Increasing evidence shows that GLP-1 RAs exert pleiotropic effects on different mediators of atherogenesis, which may help explain their benefits on ASCVD events beyond cardiometabolic risk factor control (Figure 3). This evidence concerns the gene GLP1R and atherosclerosis.